Literature DB >> 26776312

Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Maurizio Pacifici1, Eileen M Shore2.   

Abstract

Activin receptor-like kinase-2 (ALK2), the product of ACVR1, is a member of the type I bone morphogenetic protein (BMP) receptor family. ALK2 exerts key and non-redundant roles in numerous developmental processes, including the specification, growth and morphogenesis of endochondral skeletal elements. There is also strong evidence that BMP signaling plays important roles in determination, differentiation and function of neural cells and tissues. Here we focus on the intriguing discovery that common activating mutations in ALK2 occur in Fibrodysplasia Ossificans Progressiva (FOP) and Diffuse Intrinsic Pontine Gliomas (DIPGs), distinct pediatric disorders of significant severity that are associated with premature death. Pathogenesis and treatment remain elusive for both. We consider recent studies on the nature of the ACVR1 mutations, possible modes of action and targets, and plausible therapeutic measures. Comparisons of the diverse - but genetically interrelated - pathologies of FOP and DIPG will continue to be of major mutual benefit with broad biomedical and clinical relevance.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACVR1; ALK2; BMP signaling; Diffuse Intrinsic Pontine Gliomas; Fibrodysplasia Ossificans Progressiva; Orphan diseases

Mesh:

Substances:

Year:  2015        PMID: 26776312      PMCID: PMC4753137          DOI: 10.1016/j.cytogfr.2015.12.007

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  132 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

Authors:  Celia L Gregson; Peter Hollingworth; Martin Williams; Kirsten A Petrie; Alex N Bullock; Matthew A Brown; Jon H Tobias; James T Triffitt
Journal:  Bone       Date:  2010-10-29       Impact factor: 4.398

3.  Development of an ALK2-biased BMP type I receptor kinase inhibitor.

Authors:  Agustin H Mohedas; Xuechao Xing; Kelli A Armstrong; Alex N Bullock; Gregory D Cuny; Paul B Yu
Journal:  ACS Chem Biol       Date:  2013-04-30       Impact factor: 5.100

4.  Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Authors:  Andria L Culbert; Salin A Chakkalakal; Edwin G Theosmy; Tracy A Brennan; Frederick S Kaplan; Eileen M Shore
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

5.  Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.

Authors:  Michael P Whyte; Deborah Wenkert; Jennifer L Demertzis; Edward F DiCarlo; Erica Westenberg; Steven Mumm
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

6.  Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.

Authors:  Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-01       Impact factor: 11.205

7.  Sonic hedgehog--regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system.

Authors:  Q R Lu; D Yuk; J A Alberta; Z Zhu; I Pawlitzky; J Chan; A P McMahon; C D Stiles; D H Rowitch
Journal:  Neuron       Date:  2000-02       Impact factor: 17.173

8.  Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation.

Authors:  G Bhardwaj; B Murdoch; D Wu; D P Baker; K P Williams; K Chadwick; L E Ling; F N Karanu; M Bhatia
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

9.  ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development.

Authors:  Donghui Zhang; Edward M Schwarz; Randy N Rosier; Michael J Zuscik; J Edward Puzas; Regis J O'Keefe
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

10.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

Authors:  Kathryn R Taylor; Alan Mackay; Nathalène Truffaux; Yaron Butterfield; Olena Morozova; Cathy Philippe; David Castel; Catherine S Grasso; Maria Vinci; Diana Carvalho; Angel M Carcaboso; Carmen de Torres; Ofelia Cruz; Jaume Mora; Natacha Entz-Werle; Wendy J Ingram; Michelle Monje; Darren Hargrave; Alex N Bullock; Stéphanie Puget; Stephen Yip; Chris Jones; Jacques Grill
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

View more
  23 in total

1.  SOX9 keeps growth plates and articular cartilage healthy by inhibiting chondrocyte dedifferentiation/osteoblastic redifferentiation.

Authors:  Abdul Haseeb; Ranjan Kc; Marco Angelozzi; Charles de Charleroy; Danielle Rux; Robert J Tower; Lutian Yao; Renata Pellegrino da Silva; Maurizio Pacifici; Ling Qin; Véronique Lefebvre
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-23       Impact factor: 11.205

Review 2.  Activin receptor-like kinases: a diverse family playing an important role in cancer.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

3.  Identification and characterization of a novel heparan sulfate-binding domain in Activin A longest variants and implications for function.

Authors:  Evan Yang; Christina Mundy; Eric F Rappaport; Maurizio Pacifici; Paul C Billings
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 4.  Bone Morphogenetic Proteins.

Authors:  Takenobu Katagiri; Tetsuro Watabe
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-06-01       Impact factor: 10.005

Review 5.  Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.

Authors:  Maurizio Pacifici
Journal:  Bone       Date:  2017-08-19       Impact factor: 4.398

Review 6.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

7.  Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.

Authors:  Darren W Engers; Sean R Bollinger; Andrew S Felts; Anish K Vadukoot; Charles H Williams; Anna L Blobaum; Craig W Lindsley; Charles C Hong; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2020-07-17       Impact factor: 2.823

Review 8.  Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities.

Authors:  Maurizio Pacifici
Journal:  Curr Opin Pharmacol       Date:  2018-03-31       Impact factor: 5.547

9.  Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.

Authors:  Emily Murrell; Junchao Tong; David Smil; Taira Kiyota; Ahmed M Aman; Methvin B Isaac; Iain D G Watson; Neil Vasdev
Journal:  ACS Med Chem Lett       Date:  2021-04-23       Impact factor: 4.345

10.  Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.

Authors:  Deeba Ensan; David Smil; Carlos A Zepeda-Velázquez; Dimitrios Panagopoulos; Jong Fu Wong; Eleanor P Williams; Roslin Adamson; Alex N Bullock; Taira Kiyota; Ahmed Aman; Owen G Roberts; Aled M Edwards; Jeff A O'Meara; Methvin B Isaac; Rima Al-Awar
Journal:  J Med Chem       Date:  2020-05-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.